Publication | Closed Access

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Lux-lung 6MedicineRandomised Phase 3PathologyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyAfatinib Versus CisplatinLung CancerMolecular Oncology